These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 2561515

  • 1. Effect of dietary protein restriction and angiotensin converting enzyme inhibition on protein metabolism in the nephrotic syndrome.
    Don BR, Wada L, Kaysen GA, Schambelan M.
    Kidney Int Suppl; 1989 Nov; 27():S163-7. PubMed ID: 2561515
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
    Garini G, Mazzi A, Allegri L, Buzio C, Borghetti A.
    Miner Electrolyte Metab; 1996 Nov; 22(1-3):123-7. PubMed ID: 8676802
    [Abstract] [Full Text] [Related]

  • 3. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 4. Symptomatic treatment of nephrotic syndrome.
    McLigeyo SO.
    East Afr Med J; 1993 Jan; 70(1):1-2. PubMed ID: 8513718
    [No Abstract] [Full Text] [Related]

  • 5. [Protein metabolism during nephrotic syndrome. Experimental and clinical influence of dietary protein intake].
    Combe C, Aparicio M.
    Nephrologie; 1993 Jan; 14(4):171-5. PubMed ID: 8232711
    [Abstract] [Full Text] [Related]

  • 6. [Nephrotic syndrome: therapeutic possibilities].
    Meesen BP.
    Ned Tijdschr Geneeskd; 1992 May 16; 136(20):992. PubMed ID: 1317511
    [No Abstract] [Full Text] [Related]

  • 7. [Nephrotic syndrome and protein metabolism].
    Fouque D.
    Nephrologie; 1996 May 16; 17(5):279-82. PubMed ID: 8927206
    [Abstract] [Full Text] [Related]

  • 8. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
    Ravid M, Lang R, Rachmani R, Lishner M.
    Arch Intern Med; 1996 Feb 12; 156(3):286-9. PubMed ID: 8572838
    [Abstract] [Full Text] [Related]

  • 9. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Proesmans W, Van Dyck M, Devriendt K.
    Nephrol Dial Transplant; 2009 Apr 12; 24(4):1335-8. PubMed ID: 19147669
    [Abstract] [Full Text] [Related]

  • 10. The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria.
    Don BR, Kaysen GA, Hutchison FN, Schambelan M.
    Am J Kidney Dis; 1991 Jan 12; 17(1):10-7. PubMed ID: 1986564
    [Abstract] [Full Text] [Related]

  • 11. Protein diet and nephrotic syndrome.
    Olmer M, Pain C, Dussol B, Berland Y.
    Kidney Int Suppl; 1989 Nov 12; 27():S152-3. PubMed ID: 2636652
    [No Abstract] [Full Text] [Related]

  • 12. [Protein and amino acid metabolism in nephrotic syndrome (author's transl)].
    Saito A, Kobayashi S, Maeda K, Kobayashi K, Yamamoto Y, Ohta K.
    Nihon Jinzo Gakkai Shi; 1979 May 12; 21(5):493-502. PubMed ID: 529619
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK, Varma PP, Baliga KV.
    J Assoc Physicians India; 1999 Feb 12; 47(2):180-2. PubMed ID: 10999084
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
    Guazzi M, Agostoni P.
    Clin Sci (Lond); 1999 Jan 12; 96(1):17-22. PubMed ID: 9857102
    [Abstract] [Full Text] [Related]

  • 15. [Effect of diet of various protein contents on the blood fibrinolytic system in the nephrotic syndrome].
    Samsonov MA, Andreenko GV, Poliantseva LR, Agadzhanov SA, Nevraeva OG.
    Ter Arkh; 1980 Jan 12; 52(12):79-82. PubMed ID: 7245076
    [No Abstract] [Full Text] [Related]

  • 16. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ.
    Clin Physiol Biochem; 1988 Jan 12; 6(3-4):217-29. PubMed ID: 2849521
    [Abstract] [Full Text] [Related]

  • 17. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
    Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):368-75. PubMed ID: 18334254
    [Abstract] [Full Text] [Related]

  • 18. [Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
    Neverov NI, Stavrovskaia EV, Kolina IB, Shvetsov MIu, Zakharova EV, Shilov EM.
    Ter Arkh; 2001 Apr 28; 73(6):37-40. PubMed ID: 11521519
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
    Cooke HM, De Besse A.
    Int J Clin Pharmacol Ther; 1994 Feb 28; 32(2):65-70. PubMed ID: 8004361
    [Abstract] [Full Text] [Related]

  • 20. [Effect of ACE-inhibitors on changes in creatinine in the blood-- introduction].
    Sevela K, Zicha J, Pokorná V.
    Vnitr Lek; 1999 Nov 28; 45(11):650-4. PubMed ID: 10951856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.